Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resistance to human immunodeficiency virus type 1 protease inhibitors.

Literature DB >> 9797203

Resistance to human immunodeficiency virus type 1 protease inhibitors.

D Boden¹, M Markowitz.

Abstract

Entities: Species

Mesh：

Substances：

Year: 1998 PMID： 9797203 PMCID： PMC105943

Source DB: PubMed Journal: Antimicrob Agents Chemother ISSN： 0066-4804 Impact factor: 5.191

× No keyword cloud information.

78 in total

1. Studies on the role of the S4 substrate binding site of HIV proteinases.

Authors: J Tözsér; A Gustchina; I T Weber; I Blaha; E M Wondrak; S Oroszlan
Journal: FEBS Lett Date: 1991-02-25 Impact factor: 4.124

Review 2. Design of enzyme inhibitors using iterative protein crystallographic analysis.

Authors: K Appelt; R J Bacquet; C A Bartlett; C L Booth; S T Freer; M A Fuhry; M R Gehring; S M Herrmann; E F Howland; C A Janson
Journal: J Med Chem Date: 1991-07 Impact factor: 7.446

3. Second locus involved in human immunodeficiency virus type 1 resistance to protease inhibitors.

Authors: L Doyon; G Croteau; D Thibeault; F Poulin; L Pilote; D Lamarre
Journal: J Virol Date: 1996-06 Impact factor: 5.103

4. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir.

Authors: A Molla; M Korneyeva; Q Gao; S Vasavanonda; P J Schipper; H M Mo; M Markowitz; T Chernyavskiy; P Niu; N Lyons; A Hsu; G R Granneman; D D Ho; C A Boucher; J M Leonard; D W Norbeck; D J Kempf
Journal: Nat Med Date: 1996-07 Impact factor: 53.440

5. Expression of active human immunodeficiency virus type 1 protease by noninfectious chimeric virus particles.

Authors: N E Kohl; R E Diehl; E Rands; L J Davis; M G Hanobik; B Wolanski; R A Dixon
Journal: J Virol Date: 1991-06 Impact factor: 5.103

6. Kinetic characterization of human immunodeficiency virus type-1 protease-resistant variants.

Authors: S Pazhanisamy; C M Stuver; A B Cullinan; N Margolin; B G Rao; D J Livingston
Journal: J Biol Chem Date: 1996-07-26 Impact factor: 5.157

Review 7. In vivo selection of HIV-1 variants with reduced susceptibility to the protease inhibitor L-735,524 and related compounds.

Authors: E A Emini; W A Schleif; P Deutsch; J H Condra
Journal: Adv Exp Med Biol Date: 1996 Impact factor: 2.622

8. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics, and frequencies.

Authors: H Jacobsen; M Hänggi; M Ott; I B Duncan; S Owen; M Andreoni; S Vella; J Mous
Journal: J Infect Dis Date: 1996-06 Impact factor: 5.226

9. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group.

Authors: A C Collier; R W Coombs; D A Schoenfeld; R L Bassett; J Timpone; A Baruch; M Jones; K Facey; C Whitacre; V J McAuliffe; H M Friedman; T C Merigan; R C Reichman; C Hooper; L Corey
Journal: N Engl J Med Date: 1996-04-18 Impact factor: 91.245

10. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors.

Authors: M Tisdale; R E Myers; B Maschera; N R Parry; N M Oliver; E D Blair
Journal: Antimicrob Agents Chemother Date: 1995-08 Impact factor: 5.191

40 in total

1. Human immunodeficiency virus type 1 protease cleavage site mutations associated with protease inhibitor cross-resistance selected by indinavir, ritonavir, and/or saquinavir.

Authors: H C Côté; Z L Brumme; P R Harrigan
Journal: J Virol Date: 2001-01 Impact factor: 5.103

2. ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1.

Authors: L M Smeaton; V DeGruttola; G K Robbins; R W Shafer
Journal: Control Clin Trials Date: 2001-04

3. Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy.

Authors: B Rodés; A Holguín; V Soriano; M Dourana; K Mansinho; F Antunes; J González-Lahoz
Journal: J Clin Microbiol Date: 2000-04 Impact factor: 5.948

4. Analysis of HIV-1 mutation patterns in patients failing antiretroviral therapy.

Authors: E Quiros-Roldan; S Signorini; F Castelli; C Torti; A Patroni; M Airoldi; G Carosi
Journal: J Clin Lab Anal Date: 2001 Impact factor: 2.352

5. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents.

Authors: B S Robinson; K A Riccardi; Y F Gong; Q Guo; D A Stock; W S Blair; B J Terry; C A Deminie; F Djang; R J Colonno; P F Lin
Journal: Antimicrob Agents Chemother Date: 2000-08 Impact factor: 5.191